Results 141 to 150 of about 1,087,510 (314)

Drug Interaction of Dasatinib with Thymoquinone: A Pharmacokinetic Study in Rats. [PDF]

Int J Med Sci
Ahmad A, Raish M, Alkharfy KM, Jardan YAB, Ahad A, Kalam MA, Iqbal M, Abdelrahman IA, Ali N, Akhtar A, Al-Jenoobi FI.   +10 more
europepmc   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

DDI-CYP: Metabolism ensemble models for drug-drug interaction predictions. [PDF]

Drug Metab Dispos
Wong JT, Harris JS, Lane TR, Urbina F, Ekins S.   +4 more
europepmc   +1 more source

Neuronal Membrane and Drug Interaction [PDF]

, 1974
D. NAG, M. K. PODDAR, J. J. GHOSH
openalex   +1 more source

Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma

Molecular Oncology, EarlyView.
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf, Daniel Ehinger, Hans Brunnström, Mats Jönsson, Frida Rosengren, Marija Kotevska, Anna Karlsson, Mattias Aine, Christian Frezza, Maria Planck, Elsa Arbajian   +10 more
wiley   +1 more source

Graph neural network-based drug-drug interaction prediction. [PDF]

Sci Rep
Abbas K, Hao C, Yong X, Hasan MK, Islam S, Rahman AHA.   +5 more
europepmc   +1 more source

Drug interactions and lethal drug combinations

, 1975
A. Richens
openalex   +1 more source

Adverse Drug Interactions [PDF]

, 1972
S K Bhattacharya
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

PS3N: leveraging protein sequence-structure similarity for novel drug-drug interaction discovery. [PDF]

Sci Rep
Islam S, Abbasi A, Agarwal N, Zheng W, Doretto G, Adjeroh DA.   +5 more
europepmc   +1 more source